Why the study?
Does CAP combination chemotherapy improve objective response compared to CMFVP in patients with untreated metastatic breast cancer?
Population
123 patients with untreated metastatic breast cancer
Comparison
CAP combination chemotherapy vs CMFVP combination chemotherapy
Design
RCT
Authors
Loading...
CAP may be preferred for metastatic breast cancer; confirms randomized superiority in objective response.
Does CAP combination chemotherapy improve objective response compared to CMFVP in patients with untreated metastatic breast cancer?
CAP combination chemotherapy significantly improves objective response rates compared to CMFVP in untreated metastatic breast cancer, though with increased myelosuppression.
Kolarić et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: